S&P 500
(0.03%) 5 088.80 points
Dow J
(0.16%) 39 132 points
Nasdaq
(-0.28%) 15 997 points
Oil
(-2.60%) $76.57
Gas
(-8.66%) $1.582
Gold
(0.74%) $2 045.80
Silver
(0.84%) $22.98
Platinum
(0.11%) $906.50
USD/EUR
(0.04%) $0.924
USD/NOK
(0.33%) $10.53
USD/GBP
(-0.12%) $0.789
USD/RUB
(0.62%) $93.60

Realtime updates for Allogene Therapeutics Inc [ALLO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

3 days till quarter result
(bmo 2024-02-27)

Expected move: +/- 7.42%

BUY
71.43%
return 11.46%
SELL
50.00%
return -4.07%
Last Updated23 Feb 2024 @ 16:00

4.13% $ 4.54

SELL 13337 min ago

@ $4.90

Issued: 14 Feb 2024 @ 15:50


Return: -7.25%


Previous signal: Feb 14 - 13:56


Previous signal: Buy


Return: 2.30 %

Live Chart Being Loaded With Signals

Commentary (23 Feb 2024 @ 16:00):

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer...

Stats
Today's Volume 1.34M
Average Volume 3.12M
Market Cap 763.98M
EPS $-0.370 ( 2023-11-02 )
Next earnings date ( $-0.470 ) 2024-02-27
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -2.06
ATR14 $0.0060 (0.13%)
Insider Trading
Date Person Action Amount type
2024-01-25 Moore Timothy L. Buy 341 515 Stock Option (Right to buy)
2024-01-25 Moore Timothy L. Buy 96 600 Common Stock
2024-01-25 Douglas Earl Martin Buy 41 800 Common Stock
2024-01-25 Douglas Earl Martin Buy 147 778 Stock Option (Right to buy)
2024-01-25 Parker Geoffrey M. Buy 29 400 Common Stock
INSIDER POWER
68.61
Last 94 transactions
Buy: 35 151 813 | Sell: 32 008 417

Volume Correlation

Long: 0.39 (neutral)
Short: -0.82 (strong negative)
Signal:(71.129) Be Aware. Possible trading coming up! (swing)

Allogene Therapeutics Inc Correlation

10 Most Positive Correlations
HEPA0.96
TNYA0.956
ULCC0.955
NGM0.953
RIDE0.953
JBLU0.953
IMBI0.952
TCMD0.952
FNCH0.951
ALLR0.95
10 Most Negative Correlations
SKYA-0.962
LEGA-0.957
BRIV-0.955
ADAL-0.953
TBSAU-0.951
TBSA-0.95
CRZN-0.949
LDHA-0.949
FTPA-0.949
AGGR-0.949

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Allogene Therapeutics Inc Correlation - Currency/Commodity

The country flag -0.03
( neutral )
The country flag -0.01
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.75
( moderate )
The country flag 0.36
( neutral )

Allogene Therapeutics Inc Financials

Annual 2022
Revenue: $243 000
Gross Profit: $243 000 (100.00 %)
EPS: $-2.30
Q3 2023
Revenue: $43 000.00
Gross Profit: $43 000.00 (100.00 %)
EPS: $-0.370
Q2 2023
Revenue: $44 000.00
Gross Profit: $44 000.00 (100.00 %)
EPS: $-0.530
Q1 2023
Revenue: $52 000.00
Gross Profit: $52 000.00 (100.00 %)
EPS: $-0.680

Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

AboutLive Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators